BC mouse models were analyzed at end stage, defined as tumors reaching 1.5 cm, the animal experienced >15% weight loss, or other absolute survival event.
PDAC mouse models were analyzed at end stage, defined as tumors reaching 1.0 cm, the animal experienced >15% weight loss, or other absolute survival event.
Although neoadjuvant chemotherapy (NAC) offers an established 5% absolute survival benefit at 5 years, only the 40% of patients with a major tumor response appear to benefit.
The Antiretroviral Therapy (ART) Cohort Collaboration published models predicting progression to AIDS or death (the complement of AIDS-free survival) and death (the complement of absolute survival).
KPC experiments were performed with mice of mixed genders and mice were analyzed at end stage, defined as approximately 6 months of age or when tumors reached 1.0 cm, the animal experienced >15% weight loss, or other absolute survival event.
When only single-crown implants were evaluated, the absolute survival rate increased to 98.8%.
The absolute survival benefit was greatest for patients with severe three-vessel disease treated with bypass surgery.
In these patients, there is a trend for a relative survival advantage with PTCA, although absolute survival differences were modest.
In comparison, for patients with an operative risk of 5%, the expected 5-year mortality with surgery was 10% versus 23% with medical therapy (an absolute survival difference at 5 years of 13%).
For patients with an operative risk of 1%, the expected 5-year mortality with surgical therapy was 3% versus 8% with medical therapy (an absolute survival difference at 5 years of 5%).
Kaplan-Meier survival curves (both unadjusted and adjusted for all known imbalances in baseline prognostic factors) were used to examine absolute survival differences, and treatment pair hazard ratios from the Cox model were used to summarize average relative survival benefits.
